Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02446015
Recruitment Status : Completed
First Posted : May 15, 2015
Results First Posted : June 16, 2017
Last Update Posted : July 2, 2018
Sponsor:
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
The purpose of this study is to evaluate the clinical benefits of SYSTANE® ULTRA Lubricant Eye Drops using total ocular surface staining scores in subjects with dry eye administering it either as a scheduled regimen or as-needed after 28 days of treatment.

Condition or disease Intervention/treatment Phase
Dry Eye Syndrome Drug: SYSTANE® ULTRA Lubricant Eye Drops Not Applicable

Detailed Description:
This study consists of a 14-day Run-in Phase (between the Screening Visit and Baseline/Visit 1) and a Treatment Phase. During the Run-in Phase, subjects will discontinue current artificial tears and will be dispensed SYSTANE® ULTRA to be administered 1 drop in each eye as needed (PRN). Subjects who meet the re-evaluation criteria after the Run-in Phase will be randomized in a 1:2 manner to receive treatment with SYSTANE® ULTRA 4 times per day (QID) or PRN, respectively, for 28 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye
Actual Study Start Date : June 19, 2015
Actual Primary Completion Date : June 21, 2016
Actual Study Completion Date : June 21, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Systane

Arm Intervention/treatment
Experimental: Systane Ultra QID
SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
Drug: SYSTANE® ULTRA Lubricant Eye Drops
Other Name: SYSTANE® ULTRA

Active Comparator: Systane Ultra PRN
SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
Drug: SYSTANE® ULTRA Lubricant Eye Drops
Other Name: SYSTANE® ULTRA




Primary Outcome Measures :
  1. Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 28 [ Time Frame: Baseline (Day 0), Day 28 ]
    The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded three areas of the ocular surface for dryness on a scale from 0 to 5, where 0 is "Absent" and 5 is "Severe." The three scores were summed for a resultant overall 0-15 score. The change from baseline was calculated as the TOSS score at Day 28 minus the TOSS score at baseline. A more negative change value indicates greater efficacy. One eye from each subject was chosen as the study eye and only the study eye was used for eye-level efficacy analyses.


Secondary Outcome Measures :
  1. Change From Baseline in Impact of Dry Eye on Everyday Life Symptom-Bother (IDEEL SB) Score at Day 28 [ Time Frame: Baseline (Day 0), Day 28 ]
    The IDEEL SB module is a 20 question patient reported outcome questionnaire that assesses the subject's symptoms of dry eye. An overall resultant calculated score ranges from 0 to 100, with higher scores indicating greater symptom bother. One eye from each subject was chosen as the study eye and only the study eye was used for eye-level efficacy analyses.

  2. Change From Baseline in IDEEL Treatment Satisfaction Scores (Treatment Effectiveness and Treatment-related Inconvenience) at Day 28 [ Time Frame: Baseline (Day 0), Day 28 ]
    The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use (Treatment Effectiveness and Treatment Inconvenience). A resultant overall 0-100 treatment satisfaction score was calculated separately for Treatment Effectiveness and Treatment Inconvenience, with higher scores indicating greater satisfaction and less treatment-related bother. One eye from each subject was chosen as the study eye and only the study eye was used for eye-level efficacy analyses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to attend all study visits.
  • Use of BAK-free artificial tear drops on an as needed basis, at least once a week, for at least 3 months prior to Screening Visit (maximum use of 4 drops a day).
  • At least one '8 hour waking period' per week during the run-in phase without using the provided artificial tear.
  • Use provided artificial tear at least once a week during run-in phase.
  • Willing to take study treatment as directed for the entire study and able to complete the study diaries as required.
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

  • Use of artificial tears, as specified in the protocol.
  • Use of topical ocular medications, as specified in the protocol.
  • Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study.
  • Any hypersensitivity to the use of the study product formulations or an allergy to any ingredient(s) contained within product formulations.
  • Ocular abnormalities, infection, or active inflammation (not associated with dry eye) as specified in the protocol.
  • Ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months prior to Screening Visit.
  • Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in the study.
  • Contact lens use within 2 weeks prior to Screening Visit, and unwilling to avoid contact lens use during the course of the study.
  • Other protocol-specified exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02446015


Sponsors and Collaborators
Alcon Research
Investigators
Layout table for investigator information
Study Director: Sr. Clinical Manager, GCRA Alcon Research

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT02446015     History of Changes
Other Study ID Numbers: EXC120-P001
First Posted: May 15, 2015    Key Record Dates
Results First Posted: June 16, 2017
Last Update Posted: July 2, 2018
Last Verified: April 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Ophthalmic Solutions
Lubricant Eye Drops
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions